Heidelberg Pharma AG
XETRA:HPHA
Heidelberg Pharma AG
Cash from Operating Activities
Heidelberg Pharma AG
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Heidelberg Pharma AG
XETRA:HPHA
|
Cash from Operating Activities
-€33.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Operating Activities
€5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Cash from Operating Activities
-€295.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Operating Activities
€18.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Cash from Operating Activities
-€2.7m
|
CAGR 3-Years
46%
|
CAGR 5-Years
44%
|
CAGR 10-Years
9%
|
|
Formycon AG
XETRA:FYB
|
Cash from Operating Activities
-€18.9m
|
CAGR 3-Years
-134%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
See Also
What is Heidelberg Pharma AG's Cash from Operating Activities?
Cash from Operating Activities
-33.7m
EUR
Based on the financial report for Nov 30, 2023, Heidelberg Pharma AG's Cash from Operating Activities amounts to -33.7m EUR.
What is Heidelberg Pharma AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-28%
Over the last year, the Cash from Operating Activities growth was -280%. The average annual Cash from Operating Activities growth rates for Heidelberg Pharma AG have been -23% over the past three years , -28% over the past five years .